about
Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.Ruxolitinib for the treatment of myelofibrosis.Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitorsRuxolitinib for the treatment of myelofibrosis: its clinical potential.Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study.
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alen Ostojic
@ast
Alen Ostojic
@en
Alen Ostojic
@es
Alen Ostojic
@nl
type
label
Alen Ostojic
@ast
Alen Ostojic
@en
Alen Ostojic
@es
Alen Ostojic
@nl
prefLabel
Alen Ostojic
@ast
Alen Ostojic
@en
Alen Ostojic
@es
Alen Ostojic
@nl
P1053
J-6448-2012
P106
P1153
35722951300
P21
P31
P3829
P496
0000-0001-8324-2176